|
Our first-class clinical development services extend well into Asia/Pacific, where the opportunity for conducting clinical trials, together with prosperous drug sales, provides potentially limitless pharmaceutical business possibilities.
Australia offers many benefits, including a favorable regulatory environment, the highest disease prevalence of asthma and melanoma in the world, and seasonal reversal for respiratory, allergy and asthma studies. It’s also cost-competitive to run studies in Australia. That’s why we have well-established operational bases in Melbourne and Sydney in Australia
as well as a presence in Auckland,
New Zealand.
We also provide a strategic base of operations in Beijing, China, with dedicated, highly qualified CRAs extensively trained in compliance with ICH GCP. With a population of over a billion, China’s unique, untapped patient populations offer great potential, whether it’s in R&D or market launch and surveillance.
For further information on countries in this region, including key contacts, please click here
Australia | China | India 
|
